SCHEMBL3303339

SCHEMBL3303339

COc1ccc2cc(C(=O)Nc3ccc([C@H]4CC[C@H](C(=O)O)CC4)cc3)ccc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 8/20 0.61
RAB9A P51151 5/20 0.56
NPC1 O15118 4/20 0.56
CASP3 P42574 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
PLG P00747 5/20 0.56
PLAT P00750 5/20 0.56
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
ALDH1A1 P00352 2/20 0.50
HDAC3 O15379 1/20 0.50
HDAC11 Q96DB2 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
TP53 P04637 1/20 0.49
ALOX15 P16050 1/20 0.49
KDM4E B2RXH2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3303343 1.00 PLAU (0.61) PLAURAB9ANPC1CASP3SENP7
SCHEMBL14113700 1.00 PLAU (0.61) PLAURAB9ANPC1CASP3SENP7
SCHEMBL3300711 0.86 DEGS1 (0.58) PLAURAB9ANPC1CASP3SENP7
SCHEMBL3300701 0.86 DEGS1 (0.58) PLAURAB9ANPC1CASP3SENP7
SCHEMBL14113698 0.86 DEGS1 (0.58) PLAURAB9ANPC1CASP3SENP7
SCHEMBL3302674 0.84 HDAC3 (0.52) PLAURAB9ANPC1CASP3SENP7
SCHEMBL3307328 0.84 HDAC3 (0.55) PLAURAB9ANPC1CASP3SENP7
SCHEMBL3302670 0.84 HDAC3 (0.52) PLAURAB9ANPC1CASP3SENP7
SCHEMBL14113697 0.84 HDAC3 (0.52) PLAURAB9ANPC1CASP3SENP7
SCHEMBL3307317 0.84 HDAC3 (0.55) PLAURAB9ANPC1CASP3SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093733-A1 AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES PROSIDION LIMITED (GB) 2010-04-15 US disclosed
US-20100093733-A1 AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES PROSIDION LIMITED (GB) 2010-04-15 US disclosed
US-20100093733-A1 AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES PROSIDION LIMITED (GB) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093733-A1 AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES CPS1, GOT2, GPR119 PLAU 1020/4885RAB9A 1908/4885NPC1 630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.